Japanese denosumab approval furthers Daiichi Sankyo's oncology ambitions
This article was originally published in Scrip
Executive Summary
Amgen's RANK ligand inhibitor denosumab has been formally approved in Japan as Ranmark through local licensee Daiichi Sankyo for the indications of bone disorders stemming from bone metastases of solid tumours and bone complications of multiple myeloma.